X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with SHASUN PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SHASUN PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SHASUN PHARMA DISHMAN PHARMA/
SHASUN PHARMA
 
P/E (TTM) x 25.1 123.9 20.2% View Chart
P/BV x 3.3 8.5 39.2% View Chart
Dividend Yield % 0.7 0.2 284.9%  

Financials

 DISHMAN PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SHASUN PHARMA
Mar-14
DISHMAN PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs37494 397.5%   
Low Rs12946 282.7%   
Sales per share (Unadj.) Rs197.8214.2 92.4%  
Earnings per share (Unadj.) Rs21.25.3 397.4%  
Cash flow per share (Unadj.) Rs34.715.8 219.5%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.81.4 55.6%  
Book value per share (Unadj.) Rs179.953.3 337.2%  
Shares outstanding (eoy) m80.6956.62 142.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.3 389.8%   
Avg P/E ratio x11.913.1 90.6%  
P/CF ratio (eoy) x7.24.4 164.0%  
Price / Book Value ratio x1.41.3 106.8%  
Dividend payout %9.418.7 50.3%   
Avg Mkt Cap Rs m20,3063,958 513.1%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3552,164 247.5%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96112,127 131.6%  
Other income Rs m265229 115.7%   
Total revenues Rs m16,22612,356 131.3%   
Gross profit Rs m4,1031,009 406.6%  
Depreciation Rs m1,091594 183.7%   
Interest Rs m944415 227.5%   
Profit before tax Rs m2,334230 1,015.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m10 -366.7%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624-73 -857.5%   
Profit after tax Rs m1,711302 566.4%  
Gross profit margin %25.78.3 309.0%  
Effective tax rate %26.7-31.7 -84.4%   
Net profit margin %10.72.5 430.3%  
BALANCE SHEET DATA
Current assets Rs m11,0186,884 160.0%   
Current liabilities Rs m9,5178,456 112.5%   
Net working cap to sales %9.4-13.0 -72.6%  
Current ratio x1.20.8 142.2%  
Inventory Days Days11062 179.3%  
Debtors Days Days35108 32.4%  
Net fixed assets Rs m16,3044,970 328.0%   
Share capital Rs m161113 142.5%   
"Free" reserves Rs m12,9072,875 448.9%   
Net worth Rs m14,5163,020 480.6%   
Long term debt Rs m4,1891,817 230.5%   
Total assets Rs m29,80513,347 223.3%  
Interest coverage x3.51.6 223.5%   
Debt to equity ratio x0.30.6 48.0%  
Sales to assets ratio x0.50.9 58.9%   
Return on assets %8.95.4 165.8%  
Return on equity %11.810.0 117.8%  
Return on capital %17.513.3 131.6%  
Exports to sales %24.846.4 53.5%   
Imports to sales %3.714.2 26.2%   
Exports (fob) Rs m3,9565,622 70.4%   
Imports (cif) Rs m5961,728 34.5%   
Fx inflow Rs m4,9525,843 84.7%   
Fx outflow Rs m6972,173 32.1%   
Net fx Rs m4,2553,669 115.9%   
CASH FLOW
From Operations Rs m2,786398 700.8%  
From Investments Rs m-1,529-1,635 93.5%  
From Financial Activity Rs m-9411,309 -71.9%  
Net Cashflow Rs m31671 444.4%  

Share Holding

Indian Promoters % 61.4 39.2 156.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 3.6 102.8%  
FIIs % 12.7 17.6 72.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 39.6 55.8%  
Shareholders   46,261 20,750 222.9%  
Pledged promoter(s) holding % 35.8 12.3 291.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PANACEA BIOTECH  BIOCON LTD  J.B.CHEMICALS  NATCO PHARMA  AJANTA PHARMA  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - AJANTA PHARMA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS